Stock 1521 FRONTAGE HOLDINGS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Frontage Holdings Corporation

Equities

1521

KYG3679P1019

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
1.3 HKD +4.00% Intraday chart for Frontage Holdings Corporation -5.11% -43.97%
Apr. 01 Frontage Holdings' Net Profit Plunges 59% in 2023 MT
Mar. 28 Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the People’s Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.

Number of employees: 1,759

Sales per Business

HKD in Million2022Weight2023Weight Delta
Laboratory Testing
47.6 %
732 37.3 % 968 47.6 % +32.31%
Drug Development
36.6 %
- - 745 36.6 % -
Drug Discovery
12.9 %
- - 262 12.9 % -
Pharmaceutical Product Development
2.9 %
- - 60 2.9 % -

Sales per region

HKD in Million2022Weight2023Weight Delta
North America
76.6 %
1,537 78.4 % 1,558 76.6 % +1.37%
China
23.4 %
423 21.6 % 476 23.4 % +12.50%

Managers

Managers TitleAgeSince
Abdul Ezaz Mutlib CEO
 Chief Executive Officer 63 17-05-31
Song Li FOU
 Founder 66 00-12-31
Jun Gao DFI
 Director of Finance/CFO 48 Jan. 01
Zhi He Li BRD
 Director/Board Member 70 18-04-15
Richard Fischetti LAW
 General Counsel - -
Ying Lung Chang SEC
 Corporate Secretary 61 -
Dong Mei Wang PRN
 Corporate Officer/Principal 61 17-05-31

Members of the board

Members of the board TitleAgeSince
Yi Fan Li BRD
 Director/Board Member 55 18-03-31
Erh Fei Liu BRD
 Director/Board Member 65 18-03-31
Song Li FOU
 Founder 66 00-12-31
Zhi He Li BRD
 Director/Board Member 70 18-04-15
Yin Zhuan BRD
 Director/Board Member 58 22-05-31
Jing Song Wang BRD
 Director/Board Member 60 -
Hao Wu BRD
 Director/Board Member 56 22-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,064,465,974 589,495,348 ( 28.55 %) 28,741,064 ( 1.392 %) 28.55 %

Shareholders

NameEquities%Valuation
HANGZHOU TIGERMED CONSULTING CO., LTD
59.99 %
1,258,984,090 59.99 % 232 M $
Song Li
7.873 %
165,241,320 7.873 % 30 M $
Kabouter Management LLC
4.925 %
103,364,990 4.925 % 19 M $
UBS SDIC Fund Management Co., Ltd.
0.9526 %
19,992,000 0.9526 % 4 M $
Fidelity Management & Research (Hong Kong) Ltd.
0.9432 %
19,795,232 0.9432 % 4 M $
Zhi He Li
0.8315 %
17,451,632 0.8315 % 3 M $
First Seafront Fund Management Co., Ltd.
0.4245 %
8,910,000 0.4245 % 2 M $
Bosera Asset Management Co., Ltd.
0.3473 %
7,290,000 0.3473 % 1 M $
GF Fund Management Co., Ltd.
0.2895 %
6,076,000 0.2895 % 1 M $
Abdul Ezaz Mutlib
0.0196 %
411,098 0.0196 % 75 638 $

Company contact information

Frontage Holdings Corp.

700 Pennsylvania Drive

19341, Exton

+

http://www.frontagelab.com
address Frontage Holdings Corporation(1521)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Frontage Holdings Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.1661 USD
Average target price
0.2178 USD
Spread / Average Target
+31.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FRONTAGE HOLDINGS CORPORATION Stock Frontage Holdings Corporation
-43.97% 323M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 1521 Stock
  4. Company Frontage Holdings Corporation